<UMA 04-19>Quanitification of Chlamydia Infection through Flow Cytometry and Anti-Chlamydial Glycolipid Exoantigen (GLXA) Antibody

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:

UMA 04-19

IP Type:

Licensable Technology

Title:

Quanitification of Chlamydia Infection through Flow Cytometry and Anti-Chlamydial Glycolipid Exoantigen (GLXA) Antibody

Inventor:

E.S. Stuart and L.H. Semprevivo

Summary:

A method of diagnosis for the presence of intracellular Chlamydia pneunmoniae and Chlamydia trachomatis by flow cytometry, borne by blood or other body fluids. This ?stealth? pathogen is frequently present, but not obvious. As a result, no tests to detect it are performed, since standard tests are invasive. This simple technique readily detects and quantifies the presence of Chlamydia, and can be used to track the efficacy of drug and vaccine treatments.

Tech Type:

Therapeutics - Drugs and Vaccines | Diagnostics/Biomarkers | Therapeutics - Drugs and Vaccines | Diagnostics/Biomarkers | Therapeutics - Drugs and Vaccines

URL:

http://amherst.cvip-umass.net/index.cfm?fuseaction=tech.index

Contact:

Office of Commercial Ventures and Intellectual Property Phone: 413-545-3606 FAX: 413-545-3632 E-Mail: cvip@research.umass.edu

Organization:

University of Massachusetts at Amherst

Display all intellectual properties for E.S. Stuart and L.H. Semprevivo
Display all intellectual properties for University of Massachusetts at Amherst